60.26
price down icon1.78%   -1.09
after-market アフターアワーズ: 59.80 -0.46 -0.76%
loading
前日終値:
$61.35
開ける:
$61.5
24時間の取引高:
1.79M
Relative Volume:
0.92
時価総額:
$11.66B
収益:
$3.29B
当期純損益:
$268.74M
株価収益率:
43.97
EPS:
1.3704
ネットキャッシュフロー:
$759.12M
1週間 パフォーマンス:
-5.76%
1か月 パフォーマンス:
-8.86%
6か月 パフォーマンス:
+8.40%
1年 パフォーマンス:
+14.52%
1日の値動き範囲:
Value
$60.17
$61.50
1週間の範囲:
Value
$60.17
$64.96
52週間の値動き範囲:
Value
$49.26
$70.98

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1067)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,221
Name
Twitter
Name
次回の収益日
2026-10-26
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BMRN icon
BMRN
Biomarin Pharmaceutical Inc
60.26 11.66B 3.29B 268.74M 759.12M 1.3704
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-27 再開されました Morgan Stanley Overweight
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
04:42 AM

BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board - simplywall.st

04:42 AM
pulisher
Sep 25, 2026

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.

Sep 25, 2026
pulisher
Sep 25, 2026

BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq - AD HOC NEWS

Sep 25, 2026
pulisher
Sep 24, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - sg.finance.yahoo.com

Sep 24, 2026
pulisher
Sep 23, 2026

BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits

Sep 23, 2026
pulisher
Sep 23, 2026

BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical Inc. (BM8.F) stock price, news, quote and history - Yahoo Finance UK

Sep 22, 2026
pulisher
Sep 22, 2026

BioMarin Pharmaceutical stock holds near its 52-week low - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 21, 2026

BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha

Sep 21, 2026
pulisher
Sep 21, 2026

BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews

Sep 21, 2026
pulisher
Sep 21, 2026

The Best Healthcare Stocks to Buy - Morningstar

Sep 21, 2026
pulisher
Sep 20, 2026

BioMarin Pharmaceutical stock holds near a $12.38 billion value - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 20, 2026

BMRN Q2 2026 Earnings: EPS Beats Estimates by 4.05% While Shares Slip 1.75%Earnings Outlook Update - careplusvn.com

Sep 20, 2026
pulisher
Sep 19, 2026

What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - finance.yahoo.com

Sep 19, 2026
pulisher
Sep 18, 2026

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance

Sep 18, 2026
pulisher
Sep 17, 2026

BioMarin options flow shows large bullish call spread targeting $100 by April 2027 - Investing.com

Sep 17, 2026
pulisher
Sep 17, 2026

BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance

Sep 17, 2026
pulisher
Sep 16, 2026

BioMarin Stops Voxzogo Development for Noonan Syndrome - The Globe and Mail

Sep 16, 2026
pulisher
Sep 16, 2026

BMO cuts BioMarin stock price target to $97 on Voxzogo focus shift - Investing.com Nigeria

Sep 16, 2026
pulisher
Sep 15, 2026

BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) - kalkinemedia.com

Sep 15, 2026
pulisher
Sep 15, 2026

BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts - Fierce Pharma

Sep 15, 2026
pulisher
Sep 15, 2026

BioMarin Announces Discontinuation of VOXZOGO Development for Pediatric Noonan Syndrome - kalkinemedia.com

Sep 15, 2026
pulisher
Sep 15, 2026

BioMarin to discontinue development of Voxzogo for Noonan syndrome in children - Investing.com

Sep 15, 2026
pulisher
Sep 15, 2026

BMRN Looks 21.8% Undervalued on GF Value™ Amid Pipeline Shift - GuruFocus

Sep 15, 2026
pulisher
Sep 15, 2026

BioMarin shelves Voxzogo in Noonan syndrome (BMRN:NASDAQ) - Seeking Alpha

Sep 15, 2026
pulisher
Sep 15, 2026

Form 8K Biomarin Pharmaceutical Inc For: 15 September By Investing.com - Investing.com Canada

Sep 15, 2026
pulisher
Sep 14, 2026

BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Pharmaceutical Inc. Announces Appointment of Robert Plenge to Its Board of Directors and Science and Technology Committee, Effective September 10, 2026 - marketscreener.com

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Pharmaceutical appoints Robert Plenge to board of directors By Investing.com - Investing.com Nigeria

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board - citybiz

Sep 14, 2026
pulisher
Sep 14, 2026

Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com - Investing.com Nigeria

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin appoints Bristol Myers Squibb executive to board - Investing.com

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin appoints Robert Plenge to its Board and Science & Technology Committee - TradingView

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - prnewswire.com

Sep 14, 2026
pulisher
Sep 14, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals - ChartMill

Sep 14, 2026
pulisher
Sep 12, 2026

BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance

Sep 12, 2026
pulisher
Sep 10, 2026

BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 10, 2026

H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com South Africa

Sep 10, 2026
pulisher
Sep 10, 2026

Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga

Sep 10, 2026
pulisher
Sep 10, 2026

H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com

Sep 10, 2026
pulisher
Sep 09, 2026

BioMarin at Wells Fargo conference: growth, pipeline and integration - Investing.com India

Sep 09, 2026
pulisher
Sep 09, 2026

BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Sep 09, 2026
pulisher
Sep 09, 2026

BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com

Sep 09, 2026
pulisher
Sep 09, 2026

BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network

Sep 09, 2026
pulisher
Sep 09, 2026

Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts - Fierce Pharma

Sep 09, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):